Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort

Clinical Infectious Diseases 2026 Open access

Read full text
Authors: Maria Isabel Sotelo-Alva, Ofrat Beyar-Katz, Judy Yan, Silvia Escribano-Serrat, Alexander P. Boardman, Mika Geva, Marina Gomez-Llobell, Jabour Halloun, Hazim Abdulkarim Khatib, Malin L. Hultcrantz, Jennifer Kimberly Lue, Sham Mailankody
+17 more Genovefa Papanicolaou, Lia M. Palomba, Jae H Park, Kai Rejeski, Jaime Sanz, Michael Scordo, Susan K. Seo, Gunjan L. Shah, Kayleen Shi, Niveen Shibli, S. Z. Usmani, Noriko Nishimura, Zainab Shahid, Miguel-Angel Perales, Roni Shouval, Mini Kamboj, Sigrun Einarsdottir
DOI: 10.1093/cid/ciag052
Cited by: 1
References: 11

Abstract

Among 667 CAR-T recipients, the 2-year cumulative incidence of RSV was 7%, with 29% of diagnosed cases progressing to LRTI. Older age and lymphopenia were associated with severity. Most infections (74%) occurred beyond day +100 (median 8 months). No RSV-attributable deaths occurred. Clinical vigilance is warranted, especially during RSV season.

Fields of Study & Subjects

Respiratory viral infections research CAR-T cell therapy research Autoimmune and Inflammatory Disorders Research

Publication details

Journal / source
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Volume
82
Issue
4
Pages
618–621
Publication date
28 January 2026
Language
EN